Minimum Effective Volume and Optimal Volume of Liposomal Bupivacaine for Ultrasound-Guided Superior Trunk Block in Arthroscopic Rotator Cuff Repair:

Minimum Effective Volume and Optimal Volume of Liposomal Bupivacaine for Superior Trunk Block in Postoperative Analgesia After Arthroscopic Rotator Cuff Repair

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600123192

Enrollment

Unknown

Registered

2026-04-22

Start date

2026-04-22

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Experimental group:Liposomal bupivacaine for superior trunk block at the supraclavicular branching-plane level

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Age 18–80 years; 2.Scheduled for elective unilateral arthroscopic rotator cuff repair; 3.ASA physical status I–III; 4.BMI between 18 and 30 kg/m^2; 5.Able to understand the study and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1.Coagulation disorder or current anticoagulant/antiplatelet therapy that may affect the safety of regional block; 2.Allergy to bupivacaine, liposomal bupivacaine, or related drugs; 3.Skin or soft tissue infection at the puncture site; 4.Severe respiratory disease or severe cardiovascular/cerebrovascular disease; 5.Pre-existing ipsilateral phrenic nerve palsy or severe thoracic/diaphragmatic disease; 6.Pre-existing ipsilateral upper-limb peripheral neuropathy or nerve injury; 7.Neuromuscular disease that may affect grip strength assessment or postoperative neurologic evaluation; 8.Previous complex surgery involving the ipsilateral neck or supraclavicular region; 9.Previous surgery on the ipsilateral shoulder; 10.Severe hepatic dysfunction or moderate-to-severe renal insufficiency; 11.Long-term opioid use; 12.Pregnancy or lactation; 13.Inability to understand or cooperate with NRS assessment, or inability to obtain evaluable preoperative diaphragmatic ultrasound images; 14.Any other condition judged by the investigator to make the patient unsuitable for participation.

Design outcomes

Primary

Measure	Time frame
90% minimum effective volume (MEV90) for successful analgesia at 24 hours after surgery;	—

Secondary

Measure	Time frame
ncidence and grading of hemidiaphragmatic paresis;Grip ratio and incidence of grip events;Postoperative pain intensity scores;Postoperative opioid consumption;	—

Countries

China

Contacts

Public ContactQing Wang

Geriatric Hospital of Nanjing Medical University

wqjss2016@126.com+86 138 5151 2980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026